



SOUTH CAROLINA REVENUE AND FISCAL AFFAIRS OFFICE
STATEMENT OF ESTIMATED FISCAL IMPACT
(803)734-0640 • RFA.SC.GOV/IMPACTS

Bill Number:	H. 4711	Introduced on January 14, 2020
Author:	Fry	
Subject:	Naloxone	
Requestor:	House Medical, Military, Public, and Municipal Affairs	
RFA Analyst(s):	A. Martin, Griffith, and Payne	
Impact Date:	January 29, 2020 Updated for Additional Agency Response	

Fiscal Impact Summary

This bill requires prescribers to offer naloxone to patients under certain conditions. This bill will have no fiscal impact on the Department of Health and Environmental Control (DHEC) or the Department of Labor, Licensing and Regulation (LLR) because it does not materially alter the oversight or regulatory duties of the agencies.

This bill will have no impact on the General Fund, Other Funds, or Federal Funds, of the Department of Disabilities and Special Needs (DDSN) because the provisions of this bill apply to less than one percent of their regional center patients, and the agency can absorb the minimal expected increase in expenditures.

This bill will have no impact on the General Fund, Other Funds, or Federal Funds, of the Department of Mental Health (DMH) because the provisions of the bill do not alter their current patient treatment practices.

This fiscal impact has been updated to include responses from DDSN and DMH.

Explanation of Fiscal Impact

Updated for additional Agency Response on January 29, 2020
Introduced on January 14, 2020

State Expenditure

This bill requires prescribers to offer a prescription for naloxone hydrochloride or a similar drug for the complete or partial reversal of opioid depression when certain conditions exist. The bill adds requirements for the prescribing physician to provide education to patients. Any prescriber that fails to provide this education to a patient will be referred to the appropriate licensing board for the imposition of administrative sanctions.

Department of Health and Environmental Control. Naloxone hydrochloride is a Schedule IV drug, which is monitored as part of DHEC's prescription monitoring program. This bill does not materially alter the oversight or regulatory duties of DHEC. Therefore, this bill will have no expenditure impact on the agency.

Department of Labor, Licensing and Regulation. The licensing boards for prescribers are under the regulation of LLR. This bill does not materially alter the oversight or regulatory duties of the boards. Therefore, this bill will have no expenditure impact on LLR.

Department of Disabilities and Special Needs. DDSN has authority over all of the state's services and programs for the treatment and training of persons with intellectual disability, related disabilities, head injuries, and spinal cord injuries. DDSN indicates the provisions of this bill would apply to less than one percent of the patients in their regional centers, and any increase in expenses would be minimal. Therefore, this bill will have no expenditure impact on DDSN.

Department of Mental Health. DMH has jurisdiction over all of the State's mental hospitals, clinics and centers, joint State and community sponsored mental health clinics and centers and facilities for the treatment and care of alcohol and drug addicts, including the authority to name each facility. Currently, DMH does not prescribe opiates outside of the hospital setting in which patients being prescribed an opioid would be under the care and supervision of medical professionals. DMH indicates the provisions of this bill will not materially alter their current practices. Therefore, this bill will not have an expenditure impact on DMH.

State Revenue

N/A

Local Expenditure and Local Revenue

N/A

Prefiled on November 20, 2019

State Expenditure

This bill requires prescribers to offer a prescription for naloxone hydrochloride or a similar drug for the complete or partial reversal of opioid depression when certain conditions exist. The bill adds requirements for the prescribing physician to provide education to patients. Any prescriber that fails to provide this education to a patient will be referred to the appropriate licensing board for the imposition of administrative sanctions.

Department of Health and Environmental Control. Naloxone hydrochloride is a Schedule IV drug, which is monitored as part of DHEC's prescription monitoring program. This bill does not materially alter the oversight or regulatory duties of DHEC. Therefore, this bill will have no expenditure impact on the agency.

Department of Labor, Licensing and Regulation. The licensing boards for prescribers are under the regulation of LLR. This bill does not materially alter the oversight or regulatory duties of the boards. Therefore, this bill will have no expenditure impact on LLR.

State Revenue

N/A

Local Expenditure and Local Revenue

N/A



Frank A. Rainwater, Executive Director